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Glucocorticoids are widely used as anti-inflammatory and chemotherapeutic agents. However, prolonged use of glucocorticoids leads to
osteoporosis. This study was designed to examine the mechanism of dexamethasone (DEX)-induced apoptosis in murine osteoblastic
MC3T3-E1 cells. Total RNA was extracted from MC3T3-E1 cells treated with 10 7 M DEX for 6 h. DEX exerted a variety of effects on
apoptotic gene expression in osteoblasts. Ribonuclease protection assays (RPA) revealed that DEX upregulated mRNA levels of caspases-1,
-3, -6, -8, -11, -12, and bcl-XL. Western blot analysis showed enhanced processing of these caspases, with the appearance of their activated
enzymes 8 h after DEX treatment. In addition, DEX also induced the activation of caspase-9. DEX elevated the levels of cleaved poly(ADP-
ribose) polymerase and lamin A, a caspase-3 and a caspase-6 substrate, respectively. Expression of bcl-XL protein level was upregulated by
DEX. Cytochrome c release was detected in the cytosol of DEX-treated cells. Furthermore, caspase-3 enzyme activity was elevated by 2-fold
after DEX treatment for 7 h. Finally, early apoptotic cells were detected in cells treated with DEX for 3 h. Our results demonstrate that DEX-
induced apoptosis involves gene activation of a number of caspases.
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Apoptosis, or programmed cell death, is crucial for a
number of processes including development, tissue homeo-
stasis, viral infection, and cancer [1–3]. Apoptosis is
characterized by cell shrinkage, membrane blebbing, chro-
matin condensation, and nuclear DNA degradation. The
mechanism of apoptosis involves a cascade of activation
of initiator and effector caspases. So far, 14 caspases have
been identified. These enzymes are involved in proteolytic
cleavage that leads to cell disassembly [4–7].
Apoptosis plays a pivotal role in the regulation of bone
turnover [8,9]. In fact, Jilka et al. [10] demonstrated that
apoptosis is the main fate for most osteoblasts. Because
bone diseases such as osteoporosis can be caused by a
relatively decreased activity or decreased numbers of osteo-
blasts, prevention of osteoblast apoptosis can be an ex-
tremely important clinical goal.0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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E-mail address: chua.chu@med.va.gov (C.C. Chua).Glucocorticoids (GC) are widely used as chemotherapeu-
tic and anti-inflammatory agents. However, prolonged ad-
ministration of glucocorticoids is one of the leading causes of
osteoporosis [11]. It is clear that glucocorticoids have detri-
mental effects on the proliferation and function of osteoblasts.
For example, dexamethasone (DEX), a synthetic GC hor-
mone, has been shown to inhibit the synthesis of fibronectin
and collagen and to stimulate collagenase synthesis [12–15].
All of these effects lead to decreased bone formation.
Several lines of evidence indicate that glucocorticoid
induces apoptosis in bone. Weinstein et al. [16] demonstrat-
ed that prednisone increases the rate of apoptosis in both
osteoblasts and osteocytes in adult mice. In addition, Gohel
et al. [17] reported that corticosterone induces apoptosis in
rat and mouse osteoblasts by decreasing bcl2/Bax ratio.
Although glucocorticoid has been shown to induce apo-
ptosis in osteoblasts, the exact mechanism and the involve-
ment of caspases in glucocorticoid-induced apoptosis in
osteoblasts are not clearly understood. In this study, we report
that DEX induced apoptosis in murine osteoblastic MC3T3-
E1 cells by activating caspases-1, -3, -6, -8, -9, -11, and -12.
In addition, DEX also upregulated the expression of bcl-XL.
C.C. Chua et al. / Biochimica et Biophysica Acta 1642 (2003) 79–85802. Materials and methods
2.1. Cell culture and materials
Murine osteoblastic MC3T3-E1 cells were cultured in a-
modified MEM (Sigma Chemical Co., St. Louis, MO)
containing 10% fetal bovine serum (FBS), 2 mM L-gluta-
mine, and 25 Ag/ml gentamicin at 37 jC in a humidified
atmosphere of 5% CO2. Cells were serially subcultured by
treatment with trypsin and were used for experimentation
between passages 5 and 15. DEX was obtained from
Calbiochem (San Diego, CA) and was used at 10 7 M
throughout the study. a-[32P]UTP was obtained from ICN
(Costa Mesa, CA). FBS was obtained from Biofluid Divi-
sion-Biosource International (Rockville, MD). Mouse apo-
ptosis gene templates mAPO1 and mAPO2 were obtained
from BD Pharmingen (San Diego, CA). Caspase-1 antibody
was purchased from Upstate Biotechnology (Lake Placid,
NY). Caspase-3 and caspase-8 antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Caspase-
6, cleaved caspase-9, cleaved PARP and lamin A antibodies
were products of Cell Signaling Technology (Beverly, MA).
Rat monoclonal caspases-11 and -12 antibodies were gen-
erous gifts from Dr. Junying Yuan of Harvard Medical
School. Mouse monoclonal actin antibody (clone AC-40)
was purchased from Sigma. Cytochrome c and COX-4
antibodies were products of BD Pharmingen and Molecular
Probes (Eugene, OR), respectively.
2.2. Ribonuclease protection assay
MC3T3-E1 cells were seeded into 100 mm dishes con-
taining a-MEM supplemented with 10% FBS. Near conflu-
ent cells were changed to a-MEM containing 0.5% FBS for
16 h before the addition of 10 7 M DEX for 6 h. Total RNA
was extracted using acid guanidinium thiocyanate-phenol-
CHCl3 extraction method. Ribonuclease protection assay
(RPA) was performed according to manufacturer’s instruc-
tions (BD Pharmingen). Briefly, murine apoptosis template
set mAPO-1 (caspases-1, -2, -3, -6, -7, -8, -11, -12, and -14)
and mAPO-2 (bcl-w, bfl1, bcl-x, bak, bax, bcl-2, bad) were
labeled with [a-32P]UTP. RNA (10 Ag) and labeled probes
were hybridized and the protected mRNAs were resolved on
a 5% denaturing polyacrylamide gel. Intensity of the band
was scanned by a Digital Imaging System (Alpha Innotech
Corp., San Leandro, CA).
2.3. Western blot analysis
Near confluent MC3T3-E1 cells in 100 mm dishes were
incubated with a-MEM containing 0.5% FBS for 16
h before treatment with 10 7 M DEX for 2, 4, or 8 h.
Cells were lysed in a buffer containing 50 mM Pipes, pH
6.5, 2 mM EDTA, 0.1% Chaps, 20 Ag/ml leupeptin, 10 Ag/
ml each of aprotinin and pepstatin, and 5 mM dithiothreitol.
Protein concentration was determined by Coomassie dyebinding assay (BioRad, Hercules, CA). Aliquots of 50 Ag of
lysates were electrophoresed on 12% SDS-PAGE and
transferred to nitrocellulose membranes. Western blot anal-
ysis was carried out with optimal dilutions of antibodies
against caspases-1, -3, -6, -8, -9, -11, -12, cleaved PARP,
lamin A, and actin. Appropriate secondary antibodies con-
jugated to horseradish peroxidase were then added for 1.5 h.
Antigen–antibody complex was detected using enhanced
chemiluminescence reagent (Amersham Pharmacia Biotech,
Piscataway, NJ). Intensity of the band was subjected to
image analysis.
2.4. Caspase-3-like activity assay
Caspase-3-like activity was assayed using CaspaTag 3
activity kit (Serologicals Corp., Norcross, GA). Briefly,
cells in 100 mm plates were treated with 10 7 M DEX
for 7 h. After trypsinization, cells were resuspended in
300 Al of wash buffer and incubated with a working
dilution of fluorochrome-labeled caspase-3 inhibitor
(FAM-DEVD-FMK) for 1 h. Cells were washed three
times with wash buffer, resuspended in PBS, and read in
a fluorescence plate reader (excitation 485 nm, emission
535 nm). Results were expressed as fluorescence units/
106 cells.
2.5. Apoptotic cell staining
Detection of early apoptotic cells was performed with
APOPercentage Apoptosis assay kit (Biocolor Co., Belfast,
Northern Ireland). Briefly, cells were seeded on gelatin-
coated chamber slides and treated with 10 7 M DEX for 3
h. Cells were then incubated with 100 Al of dye provided in
the kit for 1 h, washed, and photographed.
2.6. Cytochrome c release
Mitochondrial and cytosolic fractions were prepared
from control and DEX-treated MC3T3-E1 cells for 16
h according to the protocol of Yang et al. [18]. Cytosolic
fractions (20 Ag) and mitochondria (5 Ag) were separated on
14% SDS-PAGE and probed with cytochrome c and COX-4
antibodies.
2.7. Statistical analysis
Statistical analyses were performed by one-way ANOVA
followed by Tukey’s multiple comparison test to show dif-
ferences between means. Data were represented as meansF
S.E. P < 0.05 was considered significant.3. Results
Our first set of experiments was designed to study the
effect of DEX on the mRNA levels of caspases and bcl-2
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10 6 M) of DEX were tested and 10 7 M was found to be
optimal (results not shown). Treatment of MC3T3-E1 cells
with 10 7 M DEX for 6 h upregulated the mRNA levels of
caspases-1, -3, -6, -8, -11, and -12, whereas the mRNA
levels of caspases-2, -7, -10, and -14 remained unchanged
(Fig. 1). In addition to its effects on the aforementioned
caspases, DEX also upregulated the mRNA levels of bcl-XL
while the levels of the rest of the bcl-2 family members
remained the same (Fig. 2). Similar results were obtained
with 3 h treatment (results not shown). In these experiments,
L32 and GAPDH served as loading controls. Table 1
summarizes a quantitative analysis of the magnitude of
induction for these six caspases. The induction ranged from
1.6-fold to 3.2-fold. In addition, the mRNA level of bcl-XL
was also upregulated by 3.2-fold.
To investigate the expression of caspases at the protein
level, lysates were prepared from cells treated with DEX for
2, 4, or 8 h. Caspase-1 was present as 45, 36, 32 and 20 kDa
bands in untreated cells. After exposure to DEX, all bands
were enhanced in intensity. The smaller fragments of 36, 32,
and 20 kDa represented the cleavage products of 45 kDa
procaspase-1 (Fig. 3). Caspase-3 is the major effectorFig. 1. Caspase mRNA expression in MC3T3-E1 cells. RNAwas extracted
from MC3T3-E1 cells treated with 10 7 M DEX for 6 h. Ribonuclease
protection assay was performed with mAPO1 template set as described in
Materials and methods. The specific mRNA transcripts are labeled using
the nomenclature from the supplier. Lower panel shows shorter exposure
of L32 and GAPDH bands. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase.
Fig. 2. Message level of bcl-2 family proteins in MC3T3-E1 cells. RNA
was extracted from MC3T3-E1 cells treated with DEX for 6 h.
Ribonuclease protection assay was performed with mAPO2 template set
as described in Materials and methods. Lower panel shows shorter exposure
of L32 and GAPDH bands.cysteine protease in the apoptotic pathway. The activation
of caspase-3 was detected with an antibody that recognized
the 20 kDa fragment of the active caspase-3. Fig. 3 shows
that DEX induced the active form of caspase-3 in a time-
dependent manner. Caspase-6, another effector caspase, was
present as a 35 kDa band in untreated cells. After DEX
treatment, the 35 kDa band increased in intensity with a
concomitant appearance of the activated 15 kDa fragment.
Fig. 3 also demonstrates that DEX induced the activation of
caspase-8, as evidenced by the appearance of the 20 kDa
fragment.
Since the gene template used in our RPA studies (Fig. 1)
did not contain caspase-9, Western blot analysis was carried
Table 1
Fold inductions of mRNA levels
Control DEX Fold
Caspase-1 0.42F 0.04 0.74F 0.06a 1.8
Caspase-3 0.62F 0.04 0.99F 0.04a 1.6
Caspase-6 0.60F 0.08 1.05F 0.02a 1.8
Caspase-8 0.33F 0.02 0.56F 0.05a 1.7
Caspase-11 0.28F 0.01 0.89F 0.16a 3.2
Caspase-12 0.26F 0.06 0.79F 0.03a 3.0
Fold induction of mRNAwas determined by scanning the pixel intensity of
each band vs. the control level. GAPDH mRNA band was used to
normalize the differences in loading. Data represent meanF S.E. from six
samples.
a P < 0.05 vs. control.
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examine if DEX affected its processing. Fig. 3 shows that
DEX treatment led to the conversion of the 49 kDa
procaspase-9 to 39 and 37 kDa fragments.Fig. 3. Western blot analysis of caspases and bcl-XL. MC3T3-E1 cells were treated
with antibodies specific for caspases-1, -3, -6, -8, -9, -11, -12, cleaved PARP, lamin
Data represent three separate experiments.Procaspase-11 was barely detectable in untreated cells.
After DEX treatment, the two procaspase-11 bands (43 and
38 kDa) appeared along with a 30 kDa fragment. Caspase-
12 was present as 60, 54 and 36 kDa bands in untreated
cells. Upon DEX treatment, all of these bands were inten-
sified (Fig. 3).
Poly(ADP-ribose) polymerase (PARP) is a substrate for
caspases-3 [19], and cleaved PARP has been shown to be an
important marker for apoptosis [20]. Lamin A is a substrate
for caspase-6 and is essential for maintaining the integrity of
nuclear envelope and cellular morphology [21]. Since both
caspase-3 and caspase-6 were induced by DEX, cleaved
PARP and lamin A levels were assessed in DEX-treated
cells. As shown in Fig. 3, DEX treatment resulted in PARP
and lamin A cleavage in a time-dependent manner,
corresponding to the pattern of caspase-3 and caspase-6
activation.
Since caspase-3 is the most important effector caspase,
we examined whether DEX induced caspase-3 enzymewith or without DEX for 2, 4, or 8 h. Western blot analysis was carried out
A, and actin. Antibody against actin demonstrates equal loading of proteins.
Fig. 6. Detection of apoptotic cells by staining with APOPercentage dye.
Cells were treated with DEX for 3 h and stained with dye as described in
Materials and methods. Apoptotic cells were stained red.
Fig. 4. Effects of DEX on caspase-3-like activity. MC3T3-E1 cells in 100
mm dishes were treated with DEX for 7 h. Caspase-3 activity was
measured by a fluorochrome labeled caspase inhibitor binding assay as
described in Materials and methods. Results were expressed as fluores-
cence units/106 cells. Data represent meanF S.E. from four samples.
a =P < 0.05 vs. CON.
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to the active center of the activated enzyme [22]. Fig. 4
shows caspase-3-like activity was increased by 2-fold after 7
h of DEX treatment.
Cytochrome c release is a marker for mitochondria-
related apoptosis [23]. Western blot analysis of cytochrome
c was performed on cytosolic and mitochondrial fractions of
control and DEX-treated cells. In control cells, most cyto-
chrome c was found in the mitochondria (Fig. 5). After DEX
treatment for 16 h, the amount of cytosolic cytochrome c
was elevated, and the mitochondrial cytochrome c level was
decreased. COX-4, a mitochondrial marker, remained at the
same level.
Finally, DEX-induced apoptosis was detected by APO-
Percentage apoptosis kit, an assay that detects early apo-
ptotic event. As shown in Fig. 6, control cells had veryFig. 5. DEX induced cytochrome c release into the cytoplasm.
Mitochondrial and cytosolic fractions were prepared from cells treated
with DEX for 16 h. Western blot analysis was carried out with cytochrome
c and COX-4 antibodies.few red apoptotic cells. Upon DEX treatment for 3 h,
approximately 15% of cells became apoptotic and stained
red.4. Discussion
In this study, we show that DEX induces apoptosis in
murine osteoblastic MC3T3-E1 cells by activating caspases-
1, -3, -6, -8, -9, -11, and -12. In addition, bcl-XL was also
upregulated. We are the first to describe the induction of
caspases-1, -8, -9, -11, and -12 by DEX in osteoblasts. The
specificity of induction is indicated by the observation that
mRNA levels of caspases-2, -7, -10, and -14 and the other
bcl-2 family were not altered by DEX.
Caspases, cysteine proteases with aspartate specificity,
are important mediators of apoptosis. The activation of
caspases arises from a number of mechanisms including
transcriptional activation, regulation of IAP proteins,
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14 members of the caspase family have been isolated. They
can be categorized into three groups [6]: initiator caspases
(-8, -9, -10, and -12), effector caspases (-3, -6, and -7), and
inflammation caspases (-1, -11).
Caspase-8 is an initiator caspase that mediates signal
transduction downstream of death receptors located on the
membrane [24]. The induction of caspase-8 by DEX in
osteoblasts agrees with the report of Schmidt et al. [25] that
glucocorticoid-induced apoptosis in monocytes involved
the CD95/CD95 ligand system, which led to the activation
of both caspase-3 and caspase-8. Caspase-9 is another
initiator caspase that is involved in mitochondrial damage
[26]. In this study, DEX is shown to induce cytochrome c
release in osteoblasts (Fig. 5). Cytochrome c is known to
bind Apaf-1 and permit the recruitment of procaspase-9
[23].
Caspase-3 and caspase-6 are effector caspases that are
responsible for cleaving nucleases in addition to cellular
substrates including lamins and PARP [20,21]. Miyashita et
al. [27] reported that glucocorticoid caused activation of
caspase-6 but not caspase-3 in human pre-B leukemia 697
cells. In contrast, the present study indicates that both
caspase-3 and caspase-6 are specifically upregulated by
DEX in osteoblasts. The discrepancy between these studies
may reflect cell specificity.
Caspases-1, -4, -5, -11, -12, and -13 belong to the
caspase-1 subfamily. Our study shows that DEX upregulates
three of the six members of the caspase-1 subfamily:
caspases-1, -11, and -12. Caspase-1, which functions both
as an initiator caspase and an effector caspase, is the best
characterized enzyme in this subfamily and is known to play
a major role in inflammation [28,29]. The upregulation of
caspase-11 mRNA by DEX treatment (Fig. 1) supports
previous studies that caspase-11 is crucial for apoptosis.
Wang et al. [30] showed that caspase-11 knockout mice had
impaired production of interleukin-1h and caspase-1 medi-
ated apoptosis, indicating that caspase-11 is important for
both inflammation and apoptosis. In addition to its role in
activating caspase-1, caspase-11 also activates caspase-3
under pathological conditions [31].
We demonstrate for the first time that DEX upregulated
caspase-12 in osteoblasts. Procaspase-12 is predominantly
localized at the ER and is activated by ER stress such as
disruption of ER calcium homeostasis or accumulation of
excess protein in ER [32]. There has been evidence that
DEX increases calcium influx in several cell systems [33–
35]. The involvement of calcium in DEX-induced apoptosis
of osteoblasts awaits further investigation.
It is interesting to note that DEX induces bcl-XL, which
is an anti-apoptotic protein [36]. The induced bcl-XL may
serve as a protective anti-apoptotic factor against future
apoptotic stimuli. Alternatively, bcl-XL may be cleaved by
caspase-3, resulting in a potent apoptosis inducer, as
reported by Clem et al. [37]. The exact role of bcl-XL in
DEX-treated osteoblasts remains to be determined.Pereira et al. [38] reported that when primary fetal rat
osteoblasts were exposed to 10 6 M cortisol in the presence
of h-glycerophosphate, cell differentiation was delayed with
a decrease in the percentage of apoptotic cells and an
inhibition of caspase-3 activity. However, cortisol has no
effect on apoptosis in the absence of h-glycerophosphate. In
the present study, we demonstrate that DEX treatment led to
increased caspase-3 activity and enhanced apoptosis in
MC3T3-E1 cells, which are immortalized osteoblastic-like
cells, resembling mature osteoblasts. These opposite results
suggest that the effect of GC on osteoblasts is dependent on
cell culture conditions and stage of differentiation.
In summary, we found that DEX induces apoptosis by
upregulating caspases-1, -3, -6, -8, -9, -11, -12 in MC3T3-
E1 cells. These results suggest that strategies such as
caspase inhibitors may be developed for the treatment of
glucocorticoid-induced osteoporosis.Acknowledgements
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